Appendix 2: Task & Finish Group Definitions for end-of-life, orphan and ultra-orphan medicines
Task and Finish Group Definitions
"A medicine used to treat a condition at a stage that usually leads to death within 3 years with currently available treatments."
"A medicine with European Medicines Agency ( EMA) designated orphan status ( i.e. conditions affecting fewer than 2,500 people in a population of 5 million) or a medicine to treat an equivalent size of population irrespective of whether it has designated orphan status."
"A medicine used to treat a condition with a prevalence of 1 in 50,000 or less (or around 100 people in Scotland)".
There is a problem
Thanks for your feedback